MedTrace Logo

YAZ Premenstrual Dysphoric Disorder (PMDD) in China

NCT00824187 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2014-04-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).

Conditions

  • Premenstrual Dysphoric Disorder ( PMDD)

Interventions

DRUG

EE20/DRSP(YAZ, BAY86-5300)

20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd

DRUG

Placebo

Inert tablet

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824187 on ClinicalTrials.gov